CapsoVision (CV) investor relations material

Company background and innovation

• Founded by experts in semiconductors, leveraging high-tech and healthcare intersections for capsule endoscopy innovation.

• Developed proprietary integrated circuits, optics, onboard storage, and cloud-based systems for remote video review.

• Built the largest image data trove in the capsule industry, enabling advanced AI training and validation.

• IPO driven by AI-powered growth in small bowel diagnostics and expansion into colon and pancreas cancer detection.

Product overview and differentiation

• CapsoCam Plus features four cameras for 360-degree GI tract imaging, with all data stored onboard, eliminating external equipment.

• Enables single-visit procedures, including telehealth, improving patient convenience and operational efficiency.

• Targets patients with GI bleeding, Crohn's disease, cancer, and celiac disease, with bleeding cases comprising 55-60% of use.

• Competes by covering broader patient populations, including those with implants or high BMI, and offers cloud-based physician access.

Market opportunity and commercial strategy

• Small bowel and upper GI market projected at $300 million by 2030; colon market nearly $18 billion, with 20 million annual colonoscopies in the US.

• Direct sales force of 26 reps in the US, direct or distributor model in 69 countries, with expansion planned as new products launch.

• No additional sales force needed for colon product launch, leveraging existing team for operational efficiency.